Suffix-based naming conventions for biosimilars outlined in draft guidance by the US Food and Drug Administration should be abandoned, the Federal Trade Commission has urged in comments submitted to the agency.
FTC Warns FDA That Biologic Suffixes Will Curb Competition
The US Food and Drug Administration should abandon its suffix-based naming proposals for biosimilars, according to local competition regulator the Federal Trade Commission, citing a dampening effect on the market and the likelihood of confusion.
